Peregrine Pharmaceuticals' Cotara Receives Fast-Track Status

10/11/2001 | Medscape (free registration)

The FDA has granted fast-track status to Peregrine Pharmaceuticals' Cotara, an experimental treatment for recurrent glioblastoma multiforme. In pre-clinical trials, the drug showed the possibility of having broad application for a number of different types of tumors; it also showed it might become more effective with successive use. Cotara currently is in phase II trials for brain cancer and phase I studies for colorectal, pancreatic, biliary and sarcoma cancers.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care